Viewing affirmative mentions of binding of IL2 (H. sapiens)

Full-text article links are indicated by after the article reference.

Document Target Regulator Anatomy Sentence
Gillis et al. (1981)TCGFThe impaired response to TCGF was associated with decreased binding of TCGF by PHA-activated cells from old donors.
Kaplan et al. (1988)IL-2These IL-2 epitopes could not be accounted for by soluble IL-2 binding to its specific receptor or adsorbing nonspecifically to the cells.
Harel-Bellan et al. (1989)IL-2Binding of fluoresceinated IL-2 to different cell types was assessed by flow cytometry analysis, on a FACS 440 calibrated using fluoresceinated Sephadex G-25 beads.
Horst and Flad (1986)IL-2Pharmacological doses of hydrocortisone abolishes both, IL-2 binding and IL-2 response.
Wainberg et al. (1984)TCGFThis was shown by allowing known quantities of virus to interact with TCGF activity for different periods of time, followed by centrifugation of any virus-TCGF complexes.
Margolin et al. (1993)Interleukin-2Interleukin-2 (IL-2) and doxorubicin have synergistic antitumor activity in selected animal models and may interact favorably in the therapy of human tumors.
Kaplan et al. (1995)interleukin 2Self-association of interleukin 2 bound to its receptor.
Kaplan et al. (1995)IL-2Whereas previous investigations with radioiodinated IL-2 have shown binding to the alpha chain with a Kd of 10 nM, we show that unsubstituted IL-2 binds to the alpha chain but does not reach saturation between 100 and 1000 nM.
Castignolles et al. (1994)interleukin-2Human recombinant interleukin-2 can be associated and released from supramolecular biovectors (SMBVs), consisting of particles made of polymerized polysaccharides.
Smith et al. (1983)IL 2Moreover, assays that required antibody-mediated intervention of the high affinity IL 2-receptor binding were ineffectual in the identification of anti-IL 2-producing hybridomas, thus necessitating the development of immunoassays.
Smith et al. (1983)IL 2Two of three initially derived antibodies detected by enzyme-linked immunoassay were found to react specifically with IL 2 as demonstrated by antibody concentration-dependent neutralization of IL 2 activity.
Smith et al. (1983)IL 2The neutralization of cellular proliferation was specific for IL 2-reactive cells, coincided with an inhibition of IL 2 receptor binding, could be completely overcome by affinity-purified IL 2 and was species-specific; human and murine IL 2 were neutralized, whereas rat IL 2 activity remained unaffected.
Smith et al. (1983)IL 2A third antibody, although much less effective in neutralizing IL 2 activity, bound to IL 2 more avidly and functioned as an efficient immunoabsorbent.
Mills and May (1987)IL-2In the absence of the other IL-2-binding molecule, the 55-kDa molecule binds IL-2 with a relatively low affinity and the 75 kDa molecule binds IL-2 with an intermediate affinity.
Mills and May (1987)IL-2One of the earliest events following interaction of IL-2 with its receptor on the surface of cells is an increase in intracellular pH due to activation of the Na+/H+ antiport.
Duprez et al. (1992)IL2After IL2 internalization, two complexes of about 70 and 90 kDa, IL2 crosslinked to alpha and beta, respectively, were found inside the cells.
Advant et al. (1995)interleukin-2The self-association of recombinant human interleukin-2 (rhIL-2) in solution was investigated as a function of pH and temperature using equilibrium sedimentation.
Ten et al. (2002)IL-2After centrifugation, IL-2 was closely associated with the liposome pellet (99%).
Sosman et al. (1990)IL-2IL-2 has been associated with overly optimistic expectations and overly negative reactions from physicians and the public.
Reem et al. (1985)IL-2IL-2 receptors are expressed after 24 hr, as determined by the binding of 125I-labeled monoclonal anti-IL-2 receptor antibody 2A3, which binds equally to high- and low-affinity receptors.
Fleischmann et al. (1990)interleukin-2Partial characterization of IL-2-IN indicates that it is a heat-stable, 75 kDa complex comprised of interleukin-2 bound to another protein(s).
Horst and Flad (1987)IL-2The mechanism by which HC inhibits the binding of IL-2 is still unknown.
Duprez et al. (1985)IL-2It constitutively expresses biologically functional high-affinity cell-surface receptors for IL-2 as shown by the binding of both radiolabeled purified IL-2 and monoclonal antibodies to IL-2 receptors.
Duprez et al. (1985)IL-2In addition, it synthesizes IL-2, which is bound to cell surface receptors.
Wang et al. (1989)IL2The synergistic interaction of IL2 and FK565 on LAK-cell activity was observed for all drug concentrations used.
Meuer et al. (1984)IL-2Perhaps more importantly, the findings demonstrate that antigen-induced proliferation is mediated through an autocrine pathway involving endogenous IL-2 production, release, and subsequent binding to IL-2 receptors.
Hank et al. (1999)IL-2Using flow cytometry, we also found quantitative differences in the ability of these two preparations to bind to IL-2 receptors.
Sugamura et al. (1985)IL-2The growth inhibition is demonstrated to be due to specific binding of IL-2 to receptors on the TL cells.
Mills et al. (1990)interleukin 2Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression.
Mills et al. (1990)IL2Binding of 125I-labeled IL2 to both Mr 75,000 and 55,000 IL2 binding molecules was inhibited by suramin.
Mills et al. (1990)IL2Similar concentrations of suramin were required to inhibit binding of 125I-labeled IL2, IL2-induced tyrosine phosphorylation, and IL2-induced proliferation, suggesting that these processes may be linked.
Mills et al. (1990)IL2The ability of suramin to prevent binding of IL2 to its receptor was used to confirm that prolonged interaction of IL2 with its receptor is required to induce cell proliferation.
Onoprienko et al. (1989)IL-2Besides, monoclonal antibodies to IL-2 recognized in ELISA the 59-72 peptide, suggesting the epitope located in this region to be main one in the protein molecule.
Matsuoka et al. (1993)IL-2These results indicate that the gamma chain is involved in both mechanisms by which IL-2 associates with and dissociates from receptors, resulting in the generation of the high-affinity IL-2 receptor along with the alpha and beta chains.
Yamanaka et al. (2009)IL-2Many articles have reported that IL-2 was associated with the clinical mechanism of ulcerative colitis, but there seems no reports about such complications before.
Ohike et al. (1986)IL-2Both antibodies did not neutralize its activity, nor did they inhibit the binding of IL-2 to the receptor on target cells.
Kato and Smith (1987)IL-2Although an IL-2-binding protein has been identified by virtue of its reactivity with a monoclonal antibody that competes with IL-2 for binding (anti-Tac), the complete and precise structure of functional IL-2 receptors is still unknown.
Bettens et al. (1984)IL 2Furthermore, anti-Tac can inhibit the mitogenic signal given by endogenous IL 2, but not by in situ produced IL 2, an observation of importance to further investigations of the mechanisms by which IL 2 interacts with specific receptors to elicit proliferation.
Gelfand et al. (1987)IL2-IL2An increase in [Ca2+]i is critical for IL2 secretion in contrast to the requirements for IL2 receptor expression and IL2-IL2 receptor interaction.
Plitnick et al. (2001)IL-2Lipoteichoic acid inhibits interleukin-2 (IL-2) function by direct binding to IL-2.
Parker et al. (1984)interleukin 2Binding of interleukin 2 to gangliosides.
Parker et al. (1984)IL2We conclude that IL2 bound to exogenous gangliosides is inactive and that the carbohydrate portion of the ganglioside is crucial to its interaction with IL2.
Corley (1982)IL2We thus conclude that the direct interaction of IL2 producing cells with an antigen presenting cell is obligatory for activation and growth.
Bich-Thuy (1990)IL-2IL-2 is thought to exert its biological effects by binding to its high-affinity receptors on cell membrane.
Bich-Thuy (1990)IL-2We designed experiments such that no in vitro de novo expressed receptors, if any, could interact with IL-2, so that any biologic events triggered by IL-2 must have been mediated in the absence of the high-affinity receptors.
D’Alessandria et al. (2009)99mTc-HYNIC-IL2The peak at 18.013 min showed all the activity bound to 99mTc-HYNIC-IL2 and corresponds to the UV peak for HYNIC-IL2.
Fleury et al. (1995)IL-2Whatever the mode of IL-2 introduction, a considerable proportion of the added protein was associated with the liposomes, as determined by gel filtration and ultrafiltration/centrifugation, suggesting that IL-2 can interact with the lipid bilayer as well as being entrapped within the aqueous phase.
Friemel et al. (1987)IL 2The inhibitory activity does not decrease the binding of IL 2 to its receptor, but inhibits the IL 2 receptor expression dose dependently.
Sharom et al. (1990)IL-2Immunosuppression by gangliosides and glycophorin thus appears to occur at the IL-2-dependent stage of proliferation and may be partially due to IL-2 binding to these molecules.
Brandt et al. (1986)IL-2The antibody, termed BO-7, recognizes r-IL-2 as well as natural human IL-2 from different sources.
Uchiyama et al. (1985)IL-2Radiolabeled IL-2 binding experiments demonstrated that ATL leukemic cells could bind IL-2, and they expressed both high and low affinity IL-2 receptors, although the number of high affinity IL-2 receptor was much less than that of low affinity IL-2 receptor and that of anti-Tac binding sites.
Smith (2006)IL2The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs The interleukin-2 molecule and receptor were the first of the interleukins to be discovered and characterized at the molecular level.
Baumann et al. (1991)IL-2 promoterWe present evidence that the binding by regulatory nuclear proteins to the kappa B element of the IL-2 promoter is affected negatively by cyclosporin A and FK-506 at concentrations paralleling their immunosuppressive activity in vivo.
Najjam et al. (1998)interleukin 2Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites.
Najjam et al. (1998)interleukin 2We have previously provided compelling evidence that human recombinant interleukin 2 (IL-2) binds to the sulfated polysaccharides heparin, highly sulfated heparan sulfate and fucoidan.
Najjam et al. (1998)IL-2Here we show that IL-2 binding is dependent on heparin chain length, but with fragments as small as 15-mers retaining binding activity.
Najjam et al. (1998)IL-2In addition soluble IL-2 receptor alpha and beta polypeptides do not compete with heparin for the binding of IL-2.
Najjam et al. (1998)IL-2IL-2 bound by heparin is still recognized by two IL-2 specific monoclonal antibodies, 3H9 and H2-8, whose epitopes lie in the amino terminal region.
Najjam et al. (1998)IL-2Murine IL-2 unlike its human counterpart fails to bind to heparin.
Hellstrand and Hermodsson (1990)IL-2Interleukin-2 (IL-2) is recognized as a major activating signal for human natural killer (NK) cells.
Dukovich et al. (1987)IL-2Chemical crosslinking of 125I-labelled IL-2 bound to high-affinity IL-2 receptors produces labelling of both the p70 protein and the Tac antigen and the anti-Tac antibody blocks the crosslink detection of both of these proteins.
Mills et al. (1985)IL 2The binding of interleukin 2 (IL 2) to its receptor results in activation of the cell leading to DNA synthesis.
Lin et al. (1988)IL-2-LIn addition, biotinylated IL-2-L was capable of simultaneously binding to cell surface IL-2R and streptavidin.
Bost and Pascual (1988)IL-2Thus, it is conceivable that an anti-HIV antibody response would generate antibodies which would crossreact with IL-2.
Weigent et al. (1986)IL-2When conjugated to a carrier protein, this peptide inhibited the binding of radiolabelled IL-2 to its receptor.
Bensussan et al. (1984)IL-2-IL-2Crosslinking of Ti molecules by either the appropriate nominal antigen/MHC specificity or anti-clonotypic monoclonal antibody results in clonal expansion of such cells via induction of IL-2 receptor expression, endogenous IL-2 release and IL-2-IL-2 receptor interaction.
Chung-Park et al. (1990)interleukin-2Acalculus lymphoeosinophilic cholecystitis associated with interleukin-2 and lymphokine-activated killer cell therapy.
Chung-Park et al. (1990)interleukin-2The authors name this unusual cholecystitis acalculus lymphoeosinophilic cholecystitis and believe it to be associated with interleukin-2 and lymphokine-activated killer cell therapy.
Weigel et al. (1989)Il2The binding to the low-affinity Il2-binding protein (Tac antigen) was unimpaired.
Waldmann et al. (1988)IL-2The precise mechanism of the antitumor effects is unclear; however, the use of a MoAb that prevents the interaction of IL-2 with its receptor on ATL cells provides a rational approach for the treatment of this malignancy.
Pauza (1987)IL-2Several cDNA clones have been isolated which are expressed subsequent to IL-2 binding, and the expression of two of these genes.
Pauza (1987)IL-2Tact52 and Tact75, is regulated directly at the level of transcription; expression of the proto-oncogene c-myb is also regulated directly by IL-2 binding.
Robb et al. (1981)TCGFBinding of radiolabeled TCGF to TCGF-responsive cells was specific, in that among several growth factors and polypeptide hormones tested, only TCGF competed for binding.
Junbo et al. (1999)IL-2The ligand/IL-2 DNA complex was able to bind specifically to cell-surface receptors on the target cell and, when incubated with HepG2 cells, resulted in elevated levels of IL-2 gene expression.
Treseler et al. (1992)interleukin-2Biological activity of interleukin-2 bound to Candida albicans.
Treseler et al. (1992)IL-2Therefore, the ability of IL-2 to bind to the mannose-rich fungus Candida albicans was examined.
Treseler et al. (1992)IL-2Soluble mannan, which is rich in exposed mannose groups, inhibited binding of IL-2 to C. albicans by approximately 60%, suggesting that the lectinlike properties of IL-2 are partially responsible for its fungal binding capacity.
Treseler et al. (1992)IL-2Binding of 125I-IL-2 could not be inhibited by unlabeled IL-2, suggesting the absence of high-affinity receptors on C. albicans for IL-2.
Treseler et al. (1992)IL-2While the in vivo relevance remains to be determined, these data demonstrate that IL-2 can bind to C. albicans in vitro and thereby influence the host response to this medically important fungus.
Serres (2001)IL-2As expected, HIV-positive sera recognize human IL-2, and a cross-reactivity was found between the structurally and physically analogous antigenic sites of GP41 (HIV1) and human IL-2.
Ravindranath et al. (2001)Interleukin-2Interleukin-2 binds to ganglioside GD(1b).
Ravindranath et al. (2001)IL-2We have developed a solid matrix immunoassay to determine the binding of interleukin-2 (IL-2) to specific gangliosides.
Ravindranath et al. (2001)IL-2The assay establishes that recombinant human IL-2 binds to ganglioside GD(1b) but not to any other gangliosides (GM(1), GM(2), GM(3), GD(1a), GD(2), GD(3), and GT(1b)).
Ravindranath et al. (2001)IL-2This assay enables distinguishing the nature of the sugar moiety of the ganglioside recognized by IL-2 and establishes the dosimetry of the ganglioside-IL-2 interaction.
Helander et al. (1991)IL-2-activatedHowever, IL-2-activated killer (LAK) cells bound strongly to, and effectively killed, cell hybrids carrying human chromosome 6, but were inefficient in both assays to mouse parental cells and to cell hybrids not carrying human chromosome 6.
Kees et al. (1990)IL-2They do not express the Tac antigen, but bind IL-2 with a Kd of 650 pM.
Vespasiani Gentilucci et al. (2002)Interleukin-2Interleukin-2 (IL-2) therapy is associated with serious toxic effects on the cardiopulmonary system.
Soni et al. (1996)Interleukin-2Interleukin-2 (IL-2) is a potent immunomodulator that has been associated with the clinical development of autoimmune disorders.